Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Adocia, a biotechnology company specialized in the development of ?best-in-class? medicines from already approved therapeutic proteins, announced that it had agreed with Eli Lilly and Company not to continue further joint research under the licensing agreement signed in December 2011 relating to use of Adocia's BioChaperone technology for the formulation of fast acting insulin analog formulated with the BioChaperone technology. Consequently, the two companies have terminated the collaboration.
?We intend to pursue more actively this project by ourselves as the phase I clinical trial met the predefined clinical endpoints, hence confirming the great potential of our BioChaperone technology? said Gerard Soula, president and CEO, Adocia.
http://www.pharmabiz.com/NewsDetails.aspx?aid=76974&sid=2
?We intend to pursue more actively this project by ourselves as the phase I clinical trial met the predefined clinical endpoints, hence confirming the great potential of our BioChaperone technology? said Gerard Soula, president and CEO, Adocia.
http://www.pharmabiz.com/NewsDetails.aspx?aid=76974&sid=2
